+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 65Years
All Genders
ID04366518

Developing Personalized Treatments for Auditory Hallucinations in Psychosis Using Brain Modeling and Cholinergic Drugs

Led by Yale University · Updated on 2025-06-05

35

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Auditory verbal hallucinations are distressing symptoms experienced throughout psychotic illnesses, and between 10% and 30% of affected individuals do not respond well to antipsychotic medications. Researchers are studying how the brain processes auditory information to better understand hallucinations and guide new personalized treatments. This early-phase trial explores how manipulating brain signaling pathways may influence hallucinations by targeting the balance between sensory input and prior perceptual beliefs. The study compares two interventions rivastigmine, a drug that increases cholinergic signaling, given as a transdermal patch to participants with psychosis and frequent auditory hallucinations, and scopolamine, which blocks cholinergic receptors, given as a patch to healthy control participants. The trial involves randomized administration of these drugs or placebo patches, with imaging and behavioral testing done during controlled experimental tasks. Rivastigmine doses are applied 8 to 14 hours before fMRI scanning sessions, with multiple visits and washout periods between treatments. Participants undergo fMRI scans and complete behavioral tasks lasting about 90 minutes to measure the number of conditioned hallucinations and related computational brain activity. Researchers track changes in brain function, prior weighting in perception, and hallucination frequency to understand treatment effects. The study includes detailed clinical assessments, computational modeling, and safety monitoring, with total participation spanning several visits for each treatment condition.

CONDITIONS

Brief Title

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

Research Team

A

Albert Powers, MD, PhD

S

Silmilly Toribio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here